Analysis Of The Clinical Value Of Seven Lung Cancer Autoantibodies In The Diagnosis Of Lung Cancer

Objective:To evaluate the clinical application value of seven tumor-associated autoantibodies(seven tumor-associated autoantibodies)in lung cancer diagnosis and to investigate the relationship between imaging features and autoantibodies.Methods:From March 2019 to August 2021,302 patients were collected from the Second Thoracic Surgery Department of ShengJing Hospital of China Medical University including 220 patients as the lung cancer group and 82 patients with benign lung tumors were selected as the control group,and the level of seven tumor-associated autoantibodies(p53,PGP9.5,SOX2,GAGE7,GBU4-5,MAGE A1,CAGE)were collected.Imaging data were also collected.Analysis of the differences in the levels and positivity rates of seven tumor associated autoantibodies in different subgroups of patients.Kruskal-Wallis H test was used to compare the data of multiple groups,Mann-Whitney U test was used to compare the data between groups,and binary logistic regression was used to analyze lung cancer and related indicators.The positive rate of counting data is expressed in%.Chi-square test or Fisher’s exact test is used for comparison between groups,and ROC curve is drawn.Results:The levels of p53,SOX2,GAGE7,GBU4.5,MAGE A1 and CAGE in patients with lung cancer were significantly higher than those in benign control group.However,there was no significant difference in PGP9.5 expression between lung cancer group and benign group,P=0.071.There was no statistically significant difference in NSCLC(0,Ⅰ,Ⅱ,Ⅲ,Ⅳ)autoantibody levels in different stages.Logistic regression model increased the risk of lung cancer by 7.40 times(3.644-15.028)95%in patients with positive compared to those with negative after adjusting for the smoking and age,and the difference was statistically significant.The specificity of the seven antibodies was more than 91%,of which p53,PGP9.5 and CAGE reached 98.78%,but the sensitivity was lower than 31%.After the combined diagnosis of the seven antibodies,the sensitivity was significantly improved to 56.36%,and the specificity was still as high as 86.59%.The area of single antibody ROCAUC ranged from 0.568 to 0.661.The combined test ROCAUC area is 0.851.There was no statistical difference in the positivity rate in clinical stage,average tumor size,consolidation tumor ratio,pathological type,and nodule imaging characteristics(all P>0.05).The positive rate of seven tumor-associated autoantibodies in lymph node positive patients was higher than that in lymph node negative patients(68.40%vs 50%),and the difference was statistically significant(P=0.01).In the subgroup of invasive adenocarcinoma,the positive rate of seven tumor-associated autoantibodies was significantly higher in poorly differentiation(76.70%)than in moderately differentiation(59.60%)and well differentiation(20%)(P=0.001).Conclusion:The detection of seven autoantibodies of lung cancer has certain clinical application value for the diagnosis of lung cancer,especially for the screening of early lung cancer.Autoantibodies have certain value in predicting the prognosis of lung cancer patients.